doi: 10.1016/S0140-6736(04)16513-6.
Dangers of rosuvastatin identified before and after FDA approval
- PMID: 15220045
- DOI: 10.1016/S0140-6736(04)16513-6
Item in Clipboard
Dangers of rosuvastatin identified before and after FDA approval
Lancet.
.
No abstract available
Comment in
-
Safety and efficacy of rosuvastatin.Lancet. 2004 Jul 10-16;364(9429):135. doi: 10.1016/S0140-6736(04)16616-6. Lancet. 2004. PMID: 15246717 No abstract available.
-
Should rosuvastatin be withdrawn from the market?Lancet. 2004 Oct 30-Nov 5;364(9445):1577-8; author reply 1578-9. doi: 10.1016/S0140-6736(04)17302-9. Lancet. 2004. PMID: 15519620 No abstract available.
-
Should rosuvastatin be withdrawn from the market?Lancet. 2004 Oct 30-Nov 5;364(9445):1577; author reply 1578-9. doi: 10.1016/S0140-6736(04)17301-7. Lancet. 2004. PMID: 15519621 No abstract available.
-
Should rosuvastatin be withdrawn from the market?Lancet. 2004 Oct 30-Nov 5;364(9445):1579; discussion 1579-80. doi: 10.1016/S0140-6736(04)17304-2. Lancet. 2004. PMID: 15519624 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
